The company has been increasing its dividend for 51 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. According to the Abbvie stock technical analysis, as of 30 June, the Relative Strength Index (RSI) was pointing to neutral at 62.18. Management initially blamed slow take-up post pandemic for the drug's declining sales, but Gonzalez also told JPM Conference attendees that "new competitive entrants has significantly lowered our sales expectations for Imbruvica". I have plugged my revenue expectations into this table knowing that they closely match AbbVie management's own expectations based on what they have said in public. Both Leqembi and Donanemab are potential $5bn - $10bn selling assets, but both drugs still have safety questions to answer and not certain to be made eligible for reimbursement. Based on earnings estimates, ABBV will have a dividend payout ratio of 54.11% next year. It pays a dividend yield of 3.83%, putting its dividend yield in the top 25% of dividend-paying stocks. Build a CFD portfolio with your favourite companies. Negative dynamics for AbbVie shares will prevail with possible volatility of 1.976%. AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV.". The stocks growth marks a significant outperformance over the broader markets. The dividend payout ratio of AbbVie is 89.56%. If signs point to that happening I will likely be revising my target price upwards again, but I am playing it more conservative as nobody truly knows the scale of losses after the Humira LOE. Your current $100 investment may be up to $188.28 in 2028. It revealed that patients with moderate to severe Crohns disease receiving Abbvies Rinvoq achieved steroid-free clinical remission in significantly higher numbers than patients receiving a placebo. AbbVie Inc. (ABBV) Stock Forecast & Price Prediction For 2023 2024 2025 Not only do these companies pay handsome dividends, they typically grow revenues every year and generate wide profit margins which leads to share price upside. 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. The above table shows quarterly and annual product revenues going back to FY20, whilst the last 4 columns show revenue growth percentage between FY20 and FY21, then revenue growth between Q2'21 and Q2'22, the sequential (quarter on quarter) growth, followed by product sales as a percentage of revenues. Shareholders of record on Friday, April 14th will be given a dividend of $1.48 per share on Monday, May 15th. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. The majority of the biosimilar (more sophisticated versions of generic drugs) imitations of Humira that will contest for market share with the original will launch around the middle of 2023, including versions developed by Pfizer (PFE), Boehringer Ingelheim, Organon (OGN), Biocon, Coherus Biosciences (CHRS) and Sandoz, whilst Amgen's (AMGN) Amjevita is permitted to launch in January. But AbbVie is also keen to explore solid tumors, and I am therefore adding an additional $1.5bn of revenues from that source by 2030. View ABBV analyst ratings or view top-rated stocks. I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. This indicates that AbbVie will be able to sustain or increase its dividend. In my opinion, based on the current portfolio, AbbVie shares look undervalued below $160, but the upside above that price is limited, unless management is able to commercialize more products between now and the end of the decade, in order to achieve what looks like a very ambitious goal in driving high-single-digit revenue growth in the second half of this decade. On 14 January 2022, the FDA approved Abbvies arthritis treatment drug, Rinvoq (upadacitinib), for the treatment of adults with moderately to severely active ulcerative colitis. I have speculatively assigned peak sales of $2bn, although it should be noted that success here is far from guaranteed, although if AbbVie did succeed with ABBV916 sales could be 2 or 3x higher than my forecast. Please disable your ad-blocker and refresh. Please disable your ad-blocker and refresh. AbbVie's total revenue grew a solid 51% to $50.2 billion over the last twelve month period, compared to $33.0 billion in 2019. The most recent increase was . All rights reserved. We now expect global sales for Skyrizi to reach more than $10 billion in 2025, an increase of $2.5 billion versus our previous guidance, reflecting higher performance across basically all of the indications. Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. What other stocks do shareholders of AbbVie own? The AbbVie of today has 5 thriving divisions - Immunology, Oncology, Neuroscience, Aesthetics, and Eye Care - with the latter 3 divisions acquired from Allergan as part of AbbVie's $63bn takeover of that company. I am using a weighted average cost of capital of ~10%, which is broadly consistent with the figure I use when modelling for the other 7 members of what I term the "Big 8" US Pharmas - Johnson & Johnson, Eli Lilly, Pfizer, Merck & Co (MRK), Bristol Myers Squibb, Amgen, and Gilead Sciences (GILD) - which helps prove the accuracy of the calculation. (ABBV), MarketBeat Week in Review 2/13 - 2/17 (ABBV), The 3 Best Pharma Stocks to Buy for Big Gains in 2023 (ABBV), How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula (ABBV), AbbVie Has a Mixed Outlook After Mixed Earnings, Q4 2022 AdTheorent Holding Company Inc Earnings Call. AbbVie has said it expects to generate high-single-digit CAGR growth from 2025 to the end of the decade after revenues fall in 2023 due to Humira LOE. The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". Abbvie Stock Forecast: up to 179.050 USD! - Walletinvestor.com Out of the most recent ratings, BMO Capital Markets Gary Nachman raised its price target from $161 to $174 with an outperform rating, while Truist Financial analyst Robyn Karnauskas raised the Abbvie stock prediction from $118 to $135 while raising rating to a buy. In my last note on AbbVie (NYSE:ABBV) for Seeking Alpha - in early July - I reviewed the Big Pharma's Q1'22 earnings and looked ahead to the release of Q2'22 figures. $163.64. I am not receiving compensation for it (other than from Seeking Alpha). AbbVie's stock was trading at $161.61 on January 1st, 2023. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. z o.o., AbbVie Productos Farmacuticos Limitada, AbbVie Products LLC, AbbVie Promoo L.da, AbbVie Pte. I also considered the long-term outlook for a company that is still only 10 years old and is about to feel the impact of a loss of patent protection for its mega-blockbuster auto-immune drug Humira, which made $20.7bn of sales for the company in FY21, representing 37% of total revenues generated. Over the next nine years, experts believe that GSK's Free Cash Flow will grow at a rate of 1.98%. Capital Com is an execution-only service provider. An investment in AbbVie is not without risk, but my contention is that this Pharma is in good hands - CEO Gonzalez has made few mistakes during his near-decade in charge - and will emerge from the Humira LOE a stronger and more diverse company. If youre new to trading, then youve probably heard the wrong thing about optionsthat theyre risky, unpredictable, or difficult. We have also launched Skyrizi for PSA in rheumatology, where we're seeing strong utilization, which is driving accelerated share growth. AbbVie Stock Crumbles On Mixed Earnings, Slashes 2022 Earnings Outlook The fact that my own forecasts are less ambitious than management's reflects the fact I have not introduced new products into my forecasts, and it will be interesting to see how management performs on that front as AbbVie has not really had to have a string pipeline while Humira has delivered such dominance in the auto-immune markets. Nevertheless, AbbVie is clearly under huge pressure to protect its dominance in the immunology markets, and the signs are it has been able to do just that thanks to the launches of 2 new drugs - Skyrizi and Rinvoq. Note that analysts ABBV stock forecasts can be wrong. As such I have downgraded my own growth expectations in the forecasting table above, reducing annual growth from 7.5%, to just 2.5%, after forecasting for $5bn revenues in FY22 - down 7.5% year-on-year. Other products such as Mavyret and Creon appear to have many more years of blockbuster sales ahead of them, although it is interesting to note that AbbVie no longer reports revenues from its Women's Health division, and scarcely mentions it. What is the dividend yield for AbbVie? (6.33% Upside) Based on 15 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. Receive regular, detailed analysis focused on biotech and healthcare stocks. Abbvie has a strong pipeline of projects ahead, and has recently received US FDA approval of its ulcerative colitis drug Rinvoq. And we remain confident in our ability to achieve total sales of more than $9 billion by 2029. Abbvie Stock Forecast 2023 In the Biopharmaceutical Industry, Abbvie has been able to create a leadership position in the market in each business segment with different brand names in different business categories like Immunology, Hematologic Oncology, Neuroscience, Aesthetics, and Eye Care. AbbVie stock forecast 2022 - 2025 - 2030 with analysis AbbVie stock stood at $162.110000610352 on 2022-03-31. forecast for 2023 is $159.42, forecast for 2024 is $156.65, forecast for 2025 is $139.68, forecast for 2026 is $124.48, All content of the Dow Jones branded indices S&P Dow Jones Indices LLC 2019 and/or its affiliates. With AbbVie seemingly very confident of approvals for all 3 of these drugs, and Gonzalez suggesting they could form the basis of a "$6 billion kind of franchise" I have modelled for such an outcome by 2030. The material provided on this website is for information purposes only and should not be understood as an investment advice. American Consumer News, LLC dba MarketBeat 2010-2023. There is an element of risk to that as clinical trial failures are common, even for a giant like AbbVie, and even CEO Gonzalez may be forced to backtrack on some of his blockbuster sales projections. Wallet Investor suggested that the price could hit $300.386 in June 2027. Other approved ADC's targeting the c-Met protein, a validated target in NSCLC, include Novartis Tabrecta, which has been pegged for peak sales of ~$1.5bn, which seems a realistic target for Teliso given how large the lung cancer market is - the largest of all oncology markets. AbbVie product revenue forecasts to 2030. ABBV Stock 12 Months Forecast. By creating a free account, you agree to our, In Britain, warm hubs emerge to beat soaring energy costs, In Chicago, adapting electric buses to winters challenges, Global race to boost electric vehicle range in cold weather, Ukraine ally Kallas fights for reelection in Estonia vote, Paid express lanes grow more popular in once-reluctant South, Pot vote has Oklahoma hungry to rake in green from Texas, Home Depot Stock Earnings Slide, Long Term Value Still There, AbbVie Stock Still a Solid Buy Despite Challenges, Chief Financial Officer & Executive Vice President, BREAKING: Tiny biotech successfully treats blindness, Fed's Shocking New Plan to Control Your Money. (JPM Healthcare conference presentation), Skyrizi's performance has been particularly eye-catching. In the last two years, GSK's Free Cash Flow has grown by 0.37%, rising from 6.76B to 6.78B. Among the more notable are ImmuVen, Pharamcyclics and Allergan plc. The 21 analysts offering 1 year price forecasts for ABBV have a max estimate of and a min estimate of . My No. As well as the stock price gains AbbVie has always paid a handsome dividend - which has increased by 270% since the Pharma's inception, currently paying $1.48 per quarter, for a current yield of 4% - the highest in the large Pharmaceutical sector. Bhd., AbbVie Sp. Nevertheless, after applying the discount factor, I calculate a share price target of $151 based on DCF analysis and a slightly higher figure of $168 based on EBITDA analysis. According to the algorithm-based forecaster Wallet Investor in its Abbvie stock forecast for 2022, the price could reach $169.852 by the end of December, $199.491 by 2023 and $229.304 by 2024. (my tables). ABBV - AbbVie Stock Prediction 2025 - 2030 Thus, it is likely that ABBV will continue to find support on the dips in this type of market environment.. The companys operations span 20 countries, treating more than 60 million people and 40 conditions annually. The review period was extended by three months in order for the FDA to review additional data submitted by AbbVie. AbbVie has received a consensus rating of Hold. See AbbVie Inc. (ABBV) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Payout ratios above 75% are not desirable because they may not be sustainable. Abbvie stock price has put up an impressive performance in 2022. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. The Large Pharma sector performed remarkably well in 2022, with the "Big 8" delivering an average ~15% gain whilst the S&P 500 index fell in value, and the biotech sector was in turmoil. For the next eight years, the forecast is for Free Cash Flow to grow by . AbbVie is led by CEO and Chairman Rick Gonzalez - likely the only Pharma CEO who lacks a college degree - who has successfully defended Humira from generic drug competition by adopting a controversial strategy of continually applying for new patents related to minor changes in manufacturing methods or administration, often referred to as a "patent thicket". The division delivered >$1.65bn in sales in Q2'22, up >15% year-on-year, and with Vraylar, Ubrelvy and possibly Qulipta all earmarked for blockbuster sales - $4bn in the case of Vraylar - my forecasting suggests this division could double in size by 2030, from ~$6.6bn revenues generated in FY22, to >$13.5bn by 2030. That makes companies like AbbVie generally very attractive to investors although it should be noted that AbbVie carries a very high level of debt which stood at >$60bn as of Q322 - more or less the amount the company paid to acquire Allergan. Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. Investors do not seem to be taking the bait, however, as AbbVie's share price has slipped by >7% across the past month, and >5% across the past 5 days. AbbVie's free cash flow yield is 10.5% compared to 4.3% for Johnson & Johnson . Richard A. Gonzalez has an approval rating of 88% among the company's employees. In the last two years, Aurora Cannabis's Revenue has fallen from C$245.54M to C$245.25M - a 0.12% decrease. Finally, AbbVie was able to raise its financial . The average price target is $163.64 with a high forecast of $190.00 and a low forecast of $133.00. Most stock quote data provided by BATS. AbbVie has been increasing its dividend for 51 years. However, there are some general principles that can be followed in order to improve the accuracy of stock price predictions. Epcoritamab alone will not be sufficient to get AbbVie where it wants to be - despite some analysts believing it will be the highest grossing Pharma revenue wise by 2026. AbbVie declared a quarterly dividend on Thursday, February 16th. The firm's revenue for the quarter was up 1.6% compared to the same quarter last year. In the past I have written about the high level of competition between major Pharma in the auto-immune space - for example, for Psoriatic Arthritis the list of approved drugs includes Humira, UCB Pharma's Cimzia, Amgen's Enbrel, Johnson & Johnson's (JNJ) Stelara, Eli Lilly's (LLY) Talzt, Novartis' (NVS) Cosentyx and Bristol-Myers Squibb's (BMY) Orencia. The development of these 2 drugs has been very quick by drug development standards, and to date both have performed exceptionally well. The stock projection varied from the low price target of $135 to the high of $200. Duodopa is approved for Parkinson's Disease but Gonzalez believes that the subcutaneous non-surgical delivery system of candidate ABBV951 can "significantly expand the patient population currently addressed by Duopa", and sees the drug as yet another future blockbuster. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. All rights reserved. With Skyrizi and Rinviq - two assets developed in-house - performing so well, however, perhaps we should give management the benefit of the doubt. The company provided earnings per share (EPS) guidance of $10.70- for the period. According to 34 stock analysts, the average 12-month stock price forecast for AbbVie stock is $166.14, which predicts an increase of 7.62%. AbbVie, like its parent Abbot Laboratories, is a well-established dividend growth stock. Slide from JPM Conference 2022 presentation. I will conclude this analysis by stating that, based on all available information, market headwinds and tailwinds, competitors, and opportunities via its products and pipeline, I still consider AbbVie to be a strong investment opportunity. ABBV closed at $152.49 on 29 June, which was above its 200-day moving average (MA) of 136.42, indicating a bullish signal for the stocks price movement ahead, according to data from TradingView. A major reason behind Abbvies stellar performance amid the ongoing economic crises is the resolution of the companys Humira (adalimumab) litigation with Alvotech in March 2022. Read our dividend analysis for ABBV. Please. In this article we take a closer look at the Abbvie stock forecast, after analysing the firms latest earnings, price moving news and analyst comments. The obvious advantages of a "one and done" permanent cure make them potentially very lucrative therapies. Disclosure: I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. (my table and forecasts). AbbVie Inc. (ABBV) Analyst Ratings, Estimates & Forecasts - Yahoo Finance Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents, Timothy J Richmond and Timothy J Richmond. In-depth profiles and analysis for 20,000 public companies. AbbVie (ABBV) stock Forecast for 2021 - 2025 - PandaForecast.com AbbVie is a leader in ESG and sustainability. These are Immunology, Oncology, Neurology, Virology and Eye Care. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049. AbbVie Stock: Still A Solid Buy After Modeling Sales To 2030 Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. Under the terms of the resolution, AbbVie will grant Alvotech a non-exclusive licence to its Humira-related patents in the US, which will begin on 1 July 2023. Trading CFDs is high risk and is not suitable for everyone. Where Will AbbVie Be in 5 Years? | The Motley Fool To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. Although management reminded analysts that "Imbruvica continues to be the total market share leader across all lines of therapy in CLL", the outlook does not look especially promising. If you have an ad-blocker enabled you may be blocked from proceeding. Within the oncology division sales of Imbruvica fell 17% year-on-year.
The Quiller Memorandum Ending Explained, Articles A